Recent studies have reported that eIF5A2 is aberrantly expressed in several types of tumor cells, including rectal carcinoma, gastric cancer, ovarian cancer, bladder cancer, and colon cancer [18, 23–25]. Here, EIF5A2 is linked to ovarian carcinoma.